2-(4-碘苯基)乙酰胺 | 84863-81-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(4-碘苯基)乙酰胺
• 英文名称: 4-iodophenylacetamide
• 英文别名: (4-iodo-phenyl)-acetic acid amide；(4-Jod-phenyl)-essigsaeure-amid；2-(4-Iodophenyl)acetamide
• CAS: 84863-81-0
• 化学式: C₈H₈INO
• mdl: MFCD09743657
• 分子量: 261.062
• InChiKey: RKJMVTJNBPMLGH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  4-碘苯乙酸 、 2-(4-碘苯基)乙酰胺 在 氯化亚砜 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-碘苯乙酰氯
  参考文献：
  名称：

  Heterocyclic derivatives

  摘要：

  式(I)中的化合物，其中R.sup.1是氢或羟基；R.sup.2是氢；或R.sup.1和R.sup.2结合在一起，使得CR.sup.1 14 CR.sup.2是一个双键；X从--Ch.sub.2 CH.sub.2 --，--C.dbd.CH--，--C.tbd.C--，--CH.sub.2 O--，--OCH.sub.2，CH.sub.2 NH--，--NHCH.sub.2 --，--CH.sub.2 CO--，--COCH.sub.2 --，--CH.sub.2 S(O).sub.n --和--S(O).sub.n CH.sub.2 --中选择（其中n为0、1或2）；Ar是苯基，其上独立选择自基团（1-6C）烷基，（2-6C）烯基，（2-6C）炔基，（1-6C）烷氧基，（1-6C）烷氧羰基，（1-6C）烷氧羰基（1-6C）烷基，（1-6C）烷氧基（1-6C）烷基，（1-6C）烷基氨基，二-\x9b（1-6C）烷基！氨基，氨基甲酰基，（1-6C）烷基甲酰基，二-\x9b（1-6C）烷基！甲酰基，（1-6C）烯基和其氧肟衍生物和所述氧肟的O-（1-6C）烷基醚（1-6C）烷硫基，（1-6C）烷磺基和（1-6C）烷磺基，当被一个或多个基团选择时，从（1-6C）烷氧羰基，（1-6C）烷酰基和其氧肟衍生物和所述氧肟衍生物的O-（1-6C）烷基醚，（1-6C）烷酰胺基，（1-6C）烷酰氧基，（1-6C）烷酰氧基（1-6）烷基，氨基甲酰基，N-（1-6C）烷基甲酰基，N，N-二\x9b（1-6C）烷基！甲酰基，氨基，（1-6C）烷基氨基，二-\x9b（1-6C）烷基！氨基，（1-6C）烷氧基，（2-6C）烯氧基，（1-6C）烷硫基，（1-6C）烷磺基，（1-6C）烷磺基，卤代（1-6C）烷基（2-6C）烯基，（2-6C）炔基，苯基，苯氧基，氰基，硝基，羟基和羧基；其中Ar可能带有进一步的取代基；它们的药学上可接受的盐抑制角鲨烯合成，因此在降低血浆胆固醇水平方面有用。制备式(I)化合物的方法也被提及，以及含有它们的药物组合物及其在医学中的用途。

  公开号：

  US05919793A1
• 作为产物：
  描述：

  4-碘苯乙酸 在 氯化亚砜 作用下， 生成 2-(4-碘苯基)乙酰胺
  参考文献：
  名称：

  The role of gender and family support on dietary compliance in an African American adolescent hypertension prevention study

  摘要：

  Social support experiences vary markedly across gender groups, and little is known about the role of social support in promoting healthy dietary compliance in African American adolescents who are at increased risk for developing hypertension. This study examined the relation between gender dietary social support, and compliance to a low sodium diet. Casual blood pressures were also examined in relation to dietary compliance and gender One hundred eighty-four healthy African American adolescents (83 boys, 101 girls) participated in an intensive 5-day low sodium diet (50 mEq/24 hr) as part of a hypertension prevention program. Emotional dietary social support from family members and friends was measured at baseline. Compliance was defined as urinary sodium excretion of less than or equal to 50 mEq/24 hr at postsodium restriction. The results indicated a significant Gender x Compliance effect for positive family support (p < .05). Girls who were compliant reported higher levels of dietary support from family members (19.2 +/- 7.8) than boys who were compliant (16.9 +/- 7.0). In contrast, boys who were compliant reported lower levels of dietary support from family members (16.9 +/- 7.0) than boys who were not compliant (20.2 +/- 7.5). Systolic blood pressure showed a trend toward decreasing in compliant participants (104.4 +/- 8.4 vs. 101.7 +/- 8.0, mm Hg, p < .06), but the effect diminished when Quetelet Index (kg/m(2)) was controlled for in the analyses (p < .12). These results suggest that higher levels of emotional dietary support from family members are associated with better adherence to short-term sodium restriction for African American girls as compared to boys. Further research is needed to determine the long-term impact of social support on sodium restriction in adolescent populations.

  DOI：

  10.1207/s15324796abm2301_9

文献信息

• [EN] RORγ ANTAGONIST AND APPLICATION THEREOF IN MEDICINE<br/>[FR] ANTAGONISTE DE RORγ ET SON UTILISATION EN MÉDECINE
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2020011147A1

  公开（公告）日：2020-01-16

  Provided herein are compounds as RORγ antagonist having Formula (I). The compounds or pharmaceutical composition thereof can be used for regulating Retinoid-related orphan receptor gamma t (RORγt). Also provided herein are methods of preparation of the compounds and composition thereof, and uses thereof in treating or preventing RORγt mediated inflammation or autoimmune diseases in mammals, particularly humans.

  本文提供的化合物为具有式（I）的RORγ拮抗剂。这些化合物或其药物组成物可用于调节视黄醇相关孤儿受体γ（RORγt）。本文还提供了这些化合物及其组成物的制备方法，以及在治疗或预防哺乳动物，特别是人类中的RORγt介导的炎症或自身免疫疾病中的用途。
• The Actual Active Species of Sulfur-Modified Gold-Supported Palladium as a Highly Effective Palladium Reservoir in the Suzuki-Miyaura Coupling
  作者：Naoyuki Hoshiya、Satoshi Shuto、Mitsuhiro Arisawa

  DOI：10.1002/adsc.201000820

  日期：2011.3.28

  The actual active species of the recently developed sulfur‐modified, gold‐supported palladium material, S‐modified Au‐supported Pd (SAPd), with one of the lowest Pd‐releasing levels and high recyclability in the Suzuki–Miyaura coupling, was investigated. Also, SAPd was found to work repeatedly as an excellent Pd reservoir for liquid‐phase combinatorial synthesis.

  最近开发的硫改性的，金负载的钯材料，S改性的A u负载的Pd（SAPd）的实际活性物质是Suzuki-Miyaura偶联剂中具有最低的Pd释放水平和高可回收性的一种。调查。而且，SAPd被发现可以反复用作液相组合合成的优良Pd储层。
• Inhibitors of glycolic acid oxidase. 4-Substituted 3-hydroxy-1H-pyrrole-2,5-dione derivatives
  作者：C. S. Rooney、W. C. Randall、K. B. Streeter、C. Ziegler、E. J. Cragoe、H. Schwam、S. R. Michelson、H. W. R. Williams、E. Eichler

  DOI：10.1021/jm00359a015

  日期：1983.5

  3-hydroxy-1H-pyrrole-2,5-dione derivatives has been prepared and studied as inhibitors of glycolic acid oxidase (GAO). Compounds possessing large lipophilic 4-substituents are, in general, potent, competitive inhibitors of porcine liver GAO in vitro. Methylation of the nitrogen or the 3-hydroxy substituent reduced potency dramatically, indicating the requirement for the two acidic functions on the 1H-pyrrole-2

  已经制备了一系列广泛的新颖的4-取代的3-羟基-1H-吡咯-2，5-二酮衍生物，并作为乙醇酸氧化酶（GAO）的抑制剂进行了研究。具有大的亲脂性4-取代基的化合物通常是猪肝GAO体外的有效竞争性抑制剂。氮或3-羟基取代基的甲基化显着降低了效能，表明需要1H-吡咯-2,5-二酮核上的两个酸性功能。在大鼠肝脏灌注研究中，使用三种代表性化合物，观察到浓度依赖性抑制[1-14C]乙醇酸酯向[14C]草酸酯的转化。长期口服喂食乙二醇的大鼠4-（4'-溴[1,1'-联苯] -4-基）衍生物（83）在58天内可显着降低草酸尿水平期。
• [EN] BENZO[d]OXAZOLES AND BENZO[d]THIAZOLES AS KINASE INHIBITORS<br/>[FR] BENZO[D]OXAZOLES ET BENZO[D]THIAZOLES COMME INHIBITEURS DE LA KINASE
  申请人：FENG YANGBO

  公开号：WO2010024903A1

  公开（公告）日：2010-03-04

  Novel benzo[d]oxazole and/or benzo[d]thiazole compounds, pharmaceutical compositions containing the benzo[d]oxazole and/or benzo[d]thiazole compounds, and methods of their pharmaceutical use are disclosed. In certain embodiments, the benzo[d]oxazole and/or benzo[d]thiazole compounds affect kinase enzyme system and can be used for the treatment of disorders in which inhibition of ROCK, PKB(Akt), p70S6K, and LIMK is medically indicated.

  本发明涉及新型苯并[d]噁唑和/或苯并[d]噻唑化合物，含有苯并[d]噁唑和/或苯并[d]噻唑化合物的制药组合物，以及它们的制药用途方法。在某些实施例中，苯并[d]噁唑和/或苯并[d]噻唑化合物影响激酶酶系统，并可用于治疗需要医学上抑制ROCK、PKB(Akt)、p70S6K和LIMK的疾病。
• CATALYST PRECURSOR, METHOD FOR PRODUCING THE SAME, METHOD FOR USING THE SAME, AND REACTOR THAT USES THE SAME
  申请人：Arisawa Mitsuhiro

  公开号：US20120115714A1

  公开（公告）日：2012-05-10

  The present invention provides the catalyst precursor that has excellent safety and stability, has high stable activity retention rate, can be recycled, increases yield resulted from a reaction, and is easily processed into various forms. The catalyst precursor comprises a structure in which the entire structure is composed of gold or a gold-based alloy and the surface of the structure is modified with elemental sulfur, or at least the surface of the structure is composed of gold or a gold-based alloy and the surface of the structure is modified with elemental sulfur, and a catalytic metal compound supported on the structure, wherein the catalyst precursor has peaks derived from the catalytic metal compound and also sulfur as analyzed by photoelectron spectroscopy, and wherein the peak derived from sulfur is of the sulfur 1s orbital observed within a range of 2470 eV±2 eV in terms of the peak top position.

  本发明提供了具有优异安全性和稳定性的催化剂前体，具有高稳定活性保留率，可回收利用，提高反应产物的收率，并且易于加工成各种形式。催化剂前体包括一种结构，整个结构由金或金基合金组成，且结构表面经过元素硫的修饰，或者至少结构表面由金或金基合金组成，且结构表面经过元素硫的修饰，以及支持在结构上的催化金属化合物，其中催化剂前体具有由催化金属化合物和硫分析得出的峰值，并且硫峰值是指在峰顶位置范围为2470 eV±2 eV内观察到的硫1s轨道。